TerminatedNCT04249596
Tianeptine for Treatment Resistant Depression
Medication studyAges 21–60United States
Understand this study
Who could participate?
Listed age limits: 21 years to 60 years.
- Listed locations
- Stanford and 2 more locationsSee all locations and recruitment
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: October 14, 2020
- Recruitment status
- Terminated
- Enrollment listed in the registry
- 38
- Sponsor
- Jonathan A. Javitch, MD, PhD
- Sponsor type
- Individual investigator
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- United States
- Age range
- From 21 Years to 60 Years
- Official registry ID
- NCT04249596
- Official title
Show the full official title
Tianeptine for Treatment Resistant Depression
Recruitment & locations
TerminatedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Stanford · New York
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Jonathan A. Javitch, MD, PhD.
Does this study involve medication?
Yes. The study involves medication, including Tianeptine Sodium.
Who can participate?
Listed age limits: 21 years to 60 years.
Is this study still recruiting?
The registry lists this study as terminated.
